##gff-version 3								
##gvf-version 1.10								
##species NCBI_Taxonomy_URI=http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
MN908947.3	.	.	241	241	.	+	.	ID=ID_0;Name=c.C-25T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C-25T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	1498	1498	.	+	.	ID=ID_1;Name=p.F411F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=13;ao=398;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C1233T;aa_name=p.F411F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	1807	1807	.	+	.	ID=ID_2;Name=p.G514G;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=13;ao=372;dp=385;Reference_seq=A;Variant_seq=G;nt_name=c.A1542G;aa_name=p.G514G;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	2536	2536	.	+	.	ID=ID_3;Name=p.V757V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=220;ao=191;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C2271T;aa_name=p.V757V;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	2659	2659	.	+	.	ID=ID_4;Name=p.K798K;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G2394A;aa_name=p.K798K;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	3037	3037	.	+	.	ID=ID_5;Name=p.F924F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=411;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C2772T;aa_name=p.F924F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	6285	6285	.	+	.	ID=ID_6;Name=p.T2007I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=13;ao=398;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C6020T;aa_name=p.T2007I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	8593	8593	.	+	.	ID=ID_7;Name=p.V2776V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=13;ao=397;dp=410;Reference_seq=T;Variant_seq=C;nt_name=c.T8328C;aa_name=p.V2776V;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	9565	9565	.	+	.	ID=ID_8;Name=p.F3100F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=13;ao=396;dp=409;Reference_seq=C;Variant_seq=T;nt_name=c.C9300T;aa_name=p.F3100F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	11287	11287	.	+	.	ID=ID_9;Name=p.S3675del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=6;ao=405;dp=411;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='3676del', 'F3677del';num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	14407	14408	.	+	.	ID=ID_10;Name=p.P4715F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=398;dp=411;Reference_seq=CC;Variant_seq=TT;nt_name=c.CC14143_14144TT;aa_name=p.P4715F;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	11287	11287	.	+	.	ID=ID_9;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=6;ao=405;dp=411;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	11287	11287	.	+	.	ID=ID_9;Name=p.F3677del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=6;ao=405;dp=411;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', '3676del';num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	11287	11287	.	+	.	ID=ID_9;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=6;ao=405;dp=411;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	14407	14408	.	+	.	ID=ID_10;Name=p.P4715F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=398;dp=411;Reference_seq=CC;Variant_seq=TT;nt_name=c.CC14143_14144TT;aa_name=p.P4715F;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	17738	17738	.	+	.	ID=ID_11;Name=p.T5825I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=helicase;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_acc=YP_009725308.1;ro=274;ao=137;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C17474T;aa_name=p.T5825I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	18171	18171	.	+	.	ID=ID_12;Name=p.G5969G;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3'-to-5' exonuclease;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_acc=YP_009725309.1;ro=13;ao=398;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C17907T;aa_name=p.G5969G;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	20724	20724	.	+	.	ID=ID_13;Name=p.L6820L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=2'-O-ribose methyltransferase;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_acc=YP_009725311.1;ro=13;ao=397;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A20460G;aa_name=p.L6820L;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21137	21137	.	+	.	ID=ID_14;Name=p.K6958R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=2'-O-ribose methyltransferase;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_acc=YP_009725311.1;ro=220;ao=191;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A20873G;aa_name=p.K6958R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21717	21717	.	+	.	ID=ID_15;Name=p.Q52R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=381;dp=394;Reference_seq=A;Variant_seq=G;nt_name=c.A155G;aa_name=p.Q52R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=transmissibility;source=https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525;citation=Albertsen et al. (2021);comb_mutation='E484K', 'Q677H', 'F888L';function_description=The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21717	21717	.	+	.	ID=ID_16;Name=p.Q52R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=381;dp=394;Reference_seq=A;Variant_seq=G;nt_name=c.A155G;aa_name=p.Q52R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='A67V', 'H69del', 'V70del', 'Y144del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_17;Name=p.A67V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='H69del', 'V70del';num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'H69del', 'V70del', 'Y144del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=immunosuppression variant emergence;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/;citation=Avanzato et al. (2020);comb_mutation=;function_description=Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	"ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_19;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_19;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_16;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'V70del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_19;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_20;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_21;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='V70del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	"ID=ID_22;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_21;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_21;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='V70del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_20;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_22;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_23;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'V70del', 'Y144del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_22;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_20;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_24;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='H69del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	"ID=ID_25;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_24;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_24;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='H69del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_20;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_25;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_26;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'Y144del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_25;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'H69del';num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_20;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_21;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='V70del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	"ID=ID_22;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_21;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_21;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='V70del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_20;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_22;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_23;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'V70del', 'Y144del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21762	21764	.	+	.	ID=ID_22;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=382;dp=395;Reference_seq=CTATACATG;Variant_seq=TTA;nt_name=c.CTATACATG200_208TTA;aa_name=p.A67_V70delinsVI;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=A67_V70delinsVI;multiaa_comb_mutation='A67V', 'V70del';num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=immunosuppression variant emergence;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/;citation=Avanzato et al. (2020);comb_mutation=;function_description=Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	"ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_19;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_18;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_19;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_16;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'V70del', 'E484K', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	21990	21990	.	+	.	ID=ID_19;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=297;dp=303;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	22570	22570	.	+	.	ID=ID_27;Name=p.C336C;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=276;ao=135;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C1008T;aa_name=p.C336C;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_15;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=transmissibility;source=https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525;citation=Albertsen et al. (2021);comb_mutation='Q52R', 'Q677H', 'F888L';function_description=The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'V70del', 'Y144del', 'D614G', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_19;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_19;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'V70del', 'Y144del', 'E484K', 'Q677H', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;"
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_19;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=411;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23593	23593	.	+	.	ID=ID_15;Name=p.Q677H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=G;Variant_seq=C;nt_name=c.G2031C;aa_name=p.Q677H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=transmissibility;source=https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525;citation=Albertsen et al. (2021);comb_mutation='Q52R', 'E484K', 'F888L';function_description=The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	23593	23593	.	+	.	ID=ID_16;Name=p.Q677H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=G;Variant_seq=C;nt_name=c.G2031C;aa_name=p.Q677H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'V70del', 'Y144del', 'E484K', 'D614G', 'F888L';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	24224	24224	.	+	.	ID=ID_15;Name=p.F888L;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=T;Variant_seq=C;nt_name=c.T2662C;aa_name=p.F888L;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=transmissibility;source=https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525;citation=Albertsen et al. (2021);comb_mutation='Q52R', 'E484K', 'Q677H';function_description=The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	24224	24224	.	+	.	ID=ID_16;Name=p.F888L;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=T;Variant_seq=C;nt_name=c.T2662C;aa_name=p.F888L;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='Q52R', 'A67V', 'H69del', 'V70del', 'Y144del', 'E484K', 'D614G', 'Q677H';function_description=Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	24748	24748	.	+	.	ID=ID_32;Name=p.F1062F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=C;Variant_seq=T;nt_name=c.C3186T;aa_name=p.F1062F;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	25658	25658	.	+	.	ID=ID_33;Name=p.T89I;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=274;ao=137;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C266T;aa_name=p.T89I;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	26305	26305	.	+	.	ID=ID_34;Name=p.L21F;chrom_region=E;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C61T;aa_name=p.L21F;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	26767	26767	.	+	.	ID=ID_35;Name=p.I82T;chrom_region=M;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=T;Variant_seq=C;nt_name=c.T245C;aa_name=p.I82T;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=homoplasy;source=https://doi.org/10.1080/22221751.2021.1922097;citation=Shen et al. (2021);comb_mutation=;function_description=This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	27204	27204	.	+	.	ID=ID_36;Name=p.F2del;chrom_region=ORF6;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=410;Reference_seq=GTTT;Variant_seq=G;nt_name=c.4_6delTTT;aa_name=p.F2del;vcf_gene=ORF6;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28233	28233	.	+	.	ID=ID_37;Name=p.V114F;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=274;ao=137;dp=411;Reference_seq=G;Variant_seq=T;nt_name=c.G340T;aa_name=p.V114F;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28277	28277	.	+	.	ID=ID_38;Name=p.S2del;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=398;dp=411;Reference_seq=TCTG;Variant_seq=T;nt_name=c.5_7delCTG;aa_name=p.S2_D3delinsY;vcf_gene=N;mutation_type=;viral_lineage=B.1.525;multi_aa_name=S2_D3delinsY;multiaa_comb_mutation='D3Y';num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28308	28308	.	+	.	ID=ID_39;Name=p.A12G;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=411;Reference_seq=C;Variant_seq=G;nt_name=c.C35G;aa_name=p.A12G;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28277	28277	.	+	.	ID=ID_38;Name=p.D3Y;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=6;ao=398;dp=411;Reference_seq=TCTG;Variant_seq=T;nt_name=c.5_7delCTG;aa_name=p.S2_D3delinsY;vcf_gene=N;mutation_type=;viral_lineage=B.1.525;multi_aa_name=S2_D3delinsY;multiaa_comb_mutation='S2del';num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28308	28308	.	+	.	ID=ID_39;Name=p.A12G;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=411;Reference_seq=C;Variant_seq=G;nt_name=c.C35G;aa_name=p.A12G;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28699	28699	.	+	.	ID=ID_40;Name=p.P142P;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=397;dp=411;Reference_seq=A;Variant_seq=G;nt_name=c.A426G;aa_name=p.P142P;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	28887	28887	.	+	.	ID=ID_41;Name=p.T205I;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=13;ao=398;dp=411;Reference_seq=C;Variant_seq=T;nt_name=c.C614T;aa_name=p.T205I;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
MN908947.3	.	.	29543	29543	.	+	.	ID=ID_42;Name=c.G-15T;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=14;ao=388;dp=402;Reference_seq=G;Variant_seq=T;nt_name=c.G-15T;aa_name=;vcf_gene=ORF10;mutation_type=;viral_lineage=B.1.525;multi_aa_name=;multiaa_comb_mutation=;num_seqs=411;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Eta;status=VUM;voi_designation_date=17-Mar-2021;voc_designation_date=;vum_designation_date=20-Sep-2021;
